192 related articles for article (PubMed ID: 37505161)
1. Metachronous double primary malignant tumors with nasopharyngeal carcinoma and diffuse malignant peritoneal mesothelioma accompanied with paraneoplastic syndromes treated with nivolumab: A case report.
Tang LK; Li ZK; Xiang YL; Ma DY; Du GB
Medicine (Baltimore); 2023 Jul; 102(30):e34349. PubMed ID: 37505161
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin plus pemetrexed therapy and subsequent immune checkpoint inhibitor administration for malignant peritoneal mesothelioma without pleural lesions: Case report.
Ikushima H; Sakatani T; Ohara S; Takeshima H; Horiuchi H; Morikawa T; Usui K
Medicine (Baltimore); 2020 May; 99(22):e19956. PubMed ID: 32481365
[TBL] [Abstract][Full Text] [Related]
3. The value of BRCA-1-associated protein 1 expression and cyclin-dependent kinase inhibitor 2A deletion to distinguish peritoneal malignant mesothelioma from peritoneal location of carcinoma in effusion cytology specimens.
Althakfi W; Gazzo S; Blanchet M; Isaac S; Piaton E; Villeneuve L; Glehen O; Gilly FN; Brevet M
Cytopathology; 2020 Jan; 31(1):5-11. PubMed ID: 31713897
[TBL] [Abstract][Full Text] [Related]
4. Nivolumab for malignant peritoneal mesothelioma.
Tanaka T; Miyamoto Y; Sakai A; Fujimoto N
BMJ Case Rep; 2020 Nov; 13(11):. PubMed ID: 33257382
[TBL] [Abstract][Full Text] [Related]
5. [Diffuse malignant peritoneal mesothelioma (DMPM) - a rare diagnosis].
Habbel VSA; Mahler EA; Feyerabend B; Oldhafer KJ; Lipp MJ
Z Gastroenterol; 2020 Feb; 58(2):146-151. PubMed ID: 32050285
[TBL] [Abstract][Full Text] [Related]
6. Treatment of diffuse malignant peritoneal mesothelioma (DMPM) by cytoreductive surgery and HIPEC.
Robella M; Vaira M; Mellano A; Marsanic P; Cinquegrana A; Borsano A; Barbera M; Caneparo A; Siatis D; Sottile A; De Simone M
Minerva Chir; 2014 Feb; 69(1):9-15. PubMed ID: 24675242
[TBL] [Abstract][Full Text] [Related]
7. Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC).
Baratti D; Kusamura S; Cabras AD; Bertulli R; Hutanu I; Deraco M
Eur J Cancer; 2013 Oct; 49(15):3140-8. PubMed ID: 23831335
[TBL] [Abstract][Full Text] [Related]
8. Molecular Signatures for Combined Targeted Treatments in Diffuse Malignant Peritoneal Mesothelioma.
Belfiore A; Busico A; Bozzi F; Brich S; Dallera E; Conca E; Capone I; Gloghini A; Volpi CC; Cabras AD; Pilotti S; Baratti D; Guaglio M; Deraco M; Kusamura S; Perrone F
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31752449
[TBL] [Abstract][Full Text] [Related]
9. CT differentiation of diffuse malignant peritoneal mesothelioma and peritoneal carcinomatosis.
Liang YF; Zheng GQ; Chen YF; Song H; Yin WJ; Zhang L
J Gastroenterol Hepatol; 2016 Apr; 31(4):709-15. PubMed ID: 26645426
[TBL] [Abstract][Full Text] [Related]
10. Current concepts in the evaluation and treatment of patients with diffuse malignant peritoneal mesothelioma.
Turner K; Varghese S; Alexander HR
J Natl Compr Canc Netw; 2012 Jan; 10(1):49-57. PubMed ID: 22223869
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial.
Fennell DA; Ewings S; Ottensmeier C; Califano R; Hanna GG; Hill K; Danson S; Steele N; Nye M; Johnson L; Lord J; Middleton C; Szlosarek P; Chan S; Gaba A; Darlison L; Wells-Jordan P; Richards C; Poile C; Lester JF; Griffiths G;
Lancet Oncol; 2021 Nov; 22(11):1530-1540. PubMed ID: 34656227
[TBL] [Abstract][Full Text] [Related]
12. Multicystic and diffuse malignant peritoneal mesothelioma in children.
Vermersch S; Arnaud A; Orbach D; Andre N; Berger C; Kepenekian V; Brigand C; Fresneau B; Poli-Merol ML; Habougit C; Varlet F; Scalabre A
Pediatr Blood Cancer; 2020 Jun; 67(6):e28286. PubMed ID: 32277799
[TBL] [Abstract][Full Text] [Related]
13. Response to Ipilimumab and Nivolumab in a Patient With Malignant Peritoneal Mesothelioma.
Rizzolo A; Ah-Lan KC; Nu TNT; Alcindor T
Clin Colorectal Cancer; 2022 Dec; 21(4):371-374. PubMed ID: 36055919
[No Abstract] [Full Text] [Related]
14. Ten-year single-center experience with treatment of primary diffuse malignant peritoneal mesothelioma (DMPM) by cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
Acs M; Gerken M; Gajic I; Mayr M; Zustin J; Piso P
Langenbecks Arch Surg; 2022 Nov; 407(7):3057-3067. PubMed ID: 35732846
[TBL] [Abstract][Full Text] [Related]
15. CpG-oligodeoxynucleotides exert remarkable antitumor activity against diffuse malignant peritoneal mesothelioma orthotopic xenografts.
De Cesare M; Sfondrini L; Pennati M; De Marco C; Motta V; Tagliabue E; Deraco M; Balsari A; Zaffaroni N
J Transl Med; 2016 Jan; 14():25. PubMed ID: 26810896
[TBL] [Abstract][Full Text] [Related]
16. [A case of malignant peritoneal mesothelioma with the epithelioid histological type, successfully treated with pemetrexed plus cisplatin].
Kobayashi M; Moriwaki T; Ochi D; Saito R; Kobayashi K; Sugaya A; Akutsu D; Hamano Y; Imanishi M; Yamamoto Y; Yamada T; Nakano N; Sugano M; Hara K; Hyodo I
Gan To Kagaku Ryoho; 2014 Mar; 41(3):361-4. PubMed ID: 24743284
[TBL] [Abstract][Full Text] [Related]
17. Clinical Response of Primary Malignant Pericardial Mesothelioma with Peritoneal Dissemination to Nivolumab.
Fujiwara S; Kano Y; Maejima Y; Fujioka T; Tamura K; Kirimura S; Miyake S; Okamoto R
Intern Med; 2024 Feb; 63(4):513-519. PubMed ID: 37380459
[TBL] [Abstract][Full Text] [Related]
18. [Malignant peritoneal mesothelioma. Our experienced with triple combined therapy: cytoreduction, intraperitoneal perioperative chemotherapy and hyperthermia].
Gómez Portilla A; Cendoya I; Muriel J; Olabarria I; Guede N; Moraza N; Fernández E; Martínez de Lecea C; Magrach L; Martín E; Romero E; Aguado I; Valdovinos M; Larrabide I
Cir Esp; 2007 Feb; 81(2):82-6. PubMed ID: 17306123
[TBL] [Abstract][Full Text] [Related]
19. Diffuse malignant peritoneal mesothelioma: Evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE Database: Multi-Institutional Retrospective Study.
Kepenekian V; Elias D; Passot G; Mery E; Goere D; Delroeux D; Quenet F; Ferron G; Pezet D; Guilloit JM; Meeus P; Pocard M; Bereder JM; Abboud K; Arvieux C; Brigand C; Marchal F; Classe JM; Lorimier G; De Chaisemartin C; Guyon F; Mariani P; Ortega-Deballon P; Isaac S; Maurice C; Gilly FN; Glehen O;
Eur J Cancer; 2016 Sep; 65():69-79. PubMed ID: 27472649
[TBL] [Abstract][Full Text] [Related]
20. Cytoreductive surgery with selective versus complete parietal peritonectomy followed by hyperthermic intraperitoneal chemotherapy in patients with diffuse malignant peritoneal mesothelioma: a controlled study.
Baratti D; Kusamura S; Cabras AD; Deraco M
Ann Surg Oncol; 2012 May; 19(5):1416-24. PubMed ID: 22302266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
